Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes.
San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel form of cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.